Macular grid laser photocoagulation in uveitis.

Suttorp-Schulten, Maria S. A.; Feron, Eric J.; Postema, F.J.; Kijlstra, Aize; Rothová, Aniki

doi:10.1136/bjo.79.9.821

Cited by 17 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 To our knowledge, only one study addresses the effect of the macular grid laser in uveitis. In this study, five patients with refractory cystoid macular oedema of long duration and poor visual acuity exhibited a reduction in oedema but no significant increase in visual acuity,8 findings similar to those obtained with grid laser photocoagulation after central vein occlusion 9…”

supporting

confidence: 86%

Grid laser photocoagulation for macular oedema in uveitis or the Irvine-Gass syndrome

Lardenoye¹,

Schooneveld²,

Treffers³

et al. 1998

British Journal of Ophthalmology

View full text Add to dashboard Cite

Aims-To determine the eVect of modified macular grid photocoagulation in patients with refractory macular oedema due to uveitis or cataract extraction. Methods-In this study 20 patients with macular oedema underwent modified macular grid laser photocoagulation and were followed by means of standardised examinations (day 0, months 2, 6, and 12) consisting of best corrected visual acuity and fluorescein angiography. Results-The mean visual acuity increased from 0.16 before to 0.3 after laser treatment (p=0.013), and fluorescein leakage was significantly reduced (p=0.005). Visual prognosis was influenced by duration of the uveitis, not by sex or age. Conclusion-Modified macular grid laser photocoagulation had a beneficial eVect on macular oedema caused by uveitis or the Irvine-Gass syndrome. A prospective, randomised study is needed to determine the exact place of modified macular grid photocoagulation in the treatment of patients with inflammatory or postsurgical macular oedema. (Br J Ophthalmol

show abstract

supporting

confidence: 86%

Grid laser photocoagulation for macular oedema in uveitis or the Irvine-Gass syndrome

Lardenoye¹,

Schooneveld²,

Treffers³

et al. 1998

British Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…[20][21][22] Several measures, such as immunosuppressive medications, grid laser photocoagulation, and pars plana vitrectomy, are proposed for the treatment of cystoid macular edema (CME). [23][24][25][26] Bevacizumab is a relatively cheap full-length humanized monoclonal antibody to VEGF and is approved for the treatment of colorectal cancer. Intravitreal administration of bevacizumab has also been shown to be effective in the treatment of neovascular age-related macular degeneration (AMD), [27][28][29] proliferative retinopathy and iris neovascularization, [30][31][32] and macular edema associated with central retinal vein occlusion.…”

Section: Discussionmentioning

confidence: 99%